| Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy (NCT04692103) | University of Washington | 2021-07-10 |
| Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer (NCT03199885) | National Cancer Institute (NCI) | 2019-04-05 |
| Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer (NCT03633331) | Alliance for Clinical Trials in Oncology | 2018-08-15 |
| Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer (NCT03377101) | National Cancer Institute (NCI) | 2018-08-07 |
| Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer (NCT03477396) | City of Hope Medical Center | 2018-06-14 |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery (NCT03326258) | National Cancer Institute (NCI) | 2018-04-20 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer (NCT03432741) | Mayo Clinic | 2018-03-27 |
| Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability (NCT03428802) | Rutgers, The State University of New Jersey | 2018-03-08 |
| Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer (NCT03101748) | M.D. Anderson Cancer Center | 2018-02-19 |
| Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer (NCT03012230) | Mayo Clinic | 2017-12-06 |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity (NCT03418961) | SWOG Cancer Research Network | 2017-11-01 |
| Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer (NCT03535701) | Ohio State University Comprehensive Cancer Center | 2017-10-20 |
| Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer (NCT03106415) | Mayo Clinic | 2017-09-27 |
| Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer (NCT02971761) | City of Hope Medical Center | 2017-06-01 |
| Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer (NCT02778685) | City of Hope Medical Center | 2016-09-30 |
| Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases (NCT02595905) | National Cancer Institute (NCI) | 2016-09-15 |
| A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors (NCT02498613) | National Cancer Institute (NCI) | 2016-08-31 |
| Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord (NCT02713269) | M.D. Anderson Cancer Center | 2016-08-29 |
| Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery (NCT02658812) | M.D. Anderson Cancer Center | 2016-08-01 |
| FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy (NCT02398773) | National Cancer Institute (NCI) | 2016-05-04 |
| Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer (NCT02474173) | National Cancer Institute (NCI) | 2016-01-15 |
| Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer (NCT02311933) | National Cancer Institute (NCI) | 2015-05-28 |
| mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian (NCT02208375) | M.D. Anderson Cancer Center | 2014-11-11 |
| Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients (NCT02152943) | M.D. Anderson Cancer Center | 2014-07-17 |
| Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer (NCT02037529) | Academic and Community Cancer Research United | 2014-01-17 |
| Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy (NCT01957514) | University of Washington | 2013-10-28 |
| Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer (NCT01622868) | National Cancer Institute (NCI) | 2012-12-06 |
| Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (NCT01552434) | M.D. Anderson Cancer Center | 2012-10-16 |
| Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer (NCT01624441) | National Cancer Institute (NCI) | 2012-08-21 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533) | National Cancer Institute (NCI) | 2012-08-03 |
| Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer (NCT01463072) | City of Hope Medical Center | 2012-06-19 |
| Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only (NCT01434303) | National Cancer Institute (NCI) | 2012-01-10 |
| Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer (NCT01349959) | National Cancer Institute (NCI) | 2011-08-15 |
| Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer (NCT01351909) | National Cancer Institute (NCI) | 2011-05-02 |
| MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer (NCT01344031) | National Cancer Institute (NCI) | 2011-04-21 |
| Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer (NCT01327781) | National Cancer Institute (NCI) | 2011-03-25 |
| Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer (NCT01251874) | National Cancer Institute (NCI) | 2010-11-22 |
| RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer (NCT01217411) | National Cancer Institute (NCI) | 2010-10-01 |
| F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy (NCT02149173) | University of Washington | 2010-09-15 |
| Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer (NCT01145430) | National Cancer Institute (NCI) | 2010-06-01 |
| Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer (NCT01142401) | National Cancer Institute (NCI) | 2010-05-26 |
| Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer (NCT00699491) | National Cancer Institute (NCI) | 2008-10-31 |
| Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer (NCT00785291) | National Cancer Institute (NCI) | 2008-10-13 |
| Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (NCT00601900) | National Cancer Institute (NCI) | 2008-09-24 |
| Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive (NCT00390455) | National Cancer Institute (NCI) | 2006-09-15 |
| Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer (NCT00376688) | National Cancer Institute (NCI) | 2006-07-11 |